spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

SMi’s 5th Molecular Diagnostics Conference

SMi’s 5th Molecular Diagnostics Conference

9-11 July 2018
Holiday Inn Kensington Forum, London, UK

SMi is proud to announce their 5th Molecular Diagnostics conference. The event will take place in central London on Monday 9th and Tuesday 10th July 2018, along with two half-day post-conference workshops taking place on Wednesday 11th July 2018.

The global molecular diagnostics market is forecasted to reach over US$10 billion in the next three years, at a CAGR of 9.1% from 2016 to 2021*. In an ever-evolving universe of molecular diagnostics, it is vital to keep up with emerging and developing technology, products and applications. Furthermore, companies must comply to the constantly change regulatory environment and tackle the challenging process if implementing these regulations.

SMi welcomes you to explore the expanding market opportunities, the least diagnostics advancements and regulatory requirements at the 5th Molecular Diagnostics Conference.

This event is CPD accredited.

#SMiMolecularDx

Speaker Line-Up includes Matthew Albert, Nicholas Dale, Ana Alfirevic, Ashfaq Gilkar, Ben Courtney, Professor Kewal Jain, Matthew Albert, Miro Venturi.

Key themes for molecular diagnostics 2018:

  • Regulatory changes, challenges and outlook
  • Advances in laboratory technologies, including: biochips, nanotechnologies and proteomic technologies
  • Personalised medicine & pharmacogenomics
  • Diagnostic methods at the point of care
  • Molecular Diagnostics in Prenatal, Infectious Disease and Cancer

(*The Market Report can be found here: https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html.)

Who should attend?

Attendees will primarily be drawn from the following backgrounds/departments:

Molecular Diagnostic, Cancer Immunology, Immunobiology, Biomarkers, Radiation Oncology, Therapeutic Radiology, Translational Medicine, Translational Assays Technologies, Companion Diagnostics, Clinical Chemistry, Experimental Medicine and Diagnostics.

They will include Leads, Directors, Heads, Project Managers, Principal Investigators, Principal Scientists, Senior Scientists, Research Scientist, Professors, Researchers and Clinical Analysts, amongst others.

phone +44 (0)20 7827 6000
email events@smi-online.co.uk
web bit.ly/2Jkt0xu
email Holiday Inn Kensington Forum, London, UK
 
Print this page
Send to a friend
   
spacer
Industry Events

PDA Universe of Pre-Filled Syringes and Injection Devices

8 October - 9 November 2018, Loews Royal Pacific, Orlando, FL

At the 2018 PDA Universe of Pre-filled Syringes and Injection Devices,industry and regulatory experts will share experiences, new developments, regulatory considerations, challenges, and industry trends and best practices. This is a must-attend event for all industry professionals involved in the development, manufacturing, testing, or marketing of pre-filled syringes and injection devices.
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>


News and Press Releases

Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics

Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces bioZen – a new series of LC solutions for bioseparations in pharmaceutical, biopharmaceutical and academic research. The series encompasses both proven and entirely new media spanning two particle platforms – core-shell and thermally modified fully porous – along with new biocompatible titanium hardware. The initial bioZen product line features seven chemistries for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal antibodies, antibody-drug conjugates and biosimilars. The offering includes specific LC chemistries for the analysis of aggregates and total mAb, intact mass and fragments, peptide mapping and quantitation and glycan mapping.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement